The influence of conservative surgical practices for malignant ovarian germ cell tumors

被引:77
作者
Chan, John K. [1 ]
Tewari, Krishnansu S. [2 ]
Waller, Sarah [3 ]
Cheung, Michael K. [1 ]
Shin, Jacob Y. [1 ]
Osann, Kathryn [4 ]
Kapp, Daniel S. [5 ]
机构
[1] Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol,UCSF Helen Diller Family Compre, San Francisco, CA 94143 USA
[2] Univ Calif Irvine, Irvine Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Orange, CA 92668 USA
[3] Stanford Univ, Sch Med, Stanford Canc Ctr, Dept Obstet & Gynecol,Div Gynecol Oncol, Stanford, CA 94305 USA
[4] Univ Calif Irvine, Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Dept Med,Div Hematol & Oncol, Orange, CA 92668 USA
[5] Stanford Univ, Sch Med, Stanford Canc Ctr, Div Radiat Therapy,Dept Radiat Oncol, Stanford, CA 94305 USA
关键词
germ cell tumors; ovarian cancer; surgical practice;
D O I
10.1002/jso.21079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate demographics, survival, and surgical trends for patients with malignant ovarian germ cell tumors. Methods: SEER data abstracted from 1988 to 2001 and analyzed using Kaplan-Meier and Cox regression models. Results: Of 760 patients, the median age was 23 years. Seventy-six percent of patients presented with stage I-II disease, and 24% with stage III-IV. Fifty-five percent were immature teratomas, 32% dysgerminomas, and 13% yolk sac tumors. Fertility-preserving surgery was performed in 41.2% (n = 313) of patients. In those <45 years old, the use of fertility-preserving surgery increased from 40.5% to 44.5% to 48.4% over the time periods 1988-1992, 1993-1997, 1998-2001 (P = 0.25). The survival of patients who underwent fertility-preserving surgery was not statistically different compared to those who underwent standard surgery (P = 0.26). Patients with stage I-II disease had improved survival compared to stage III-IV disease (97.6% vs. 85.5%, P < 0.001). The overall survival of women with dysgerminomas, immature teratomas, and yolk sac tumors was 99.5%, 94.3%, and 85.4%, respectively (P < 0.001). In multivariate analysis, older age, advanced stage, and yolk sac tumor histology predicted for poorer survival. Conclusion: Our data suggests that the use of fertility-preserving surgery with concomitant surgical staging for germ cell cancers has increased without compromising survival.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 21 条
[1]   Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: An intergroup study [J].
Billmire, D ;
Vinocur, C ;
Rescorla, F ;
Cushing, B ;
London, W ;
Schlatter, M ;
Davis, M ;
Giller, R ;
Lauer, S ;
Olson, T .
JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (03) :424-429
[2]   Outcome and reproductive function after chemotherapy for ovarian dysgerminoma [J].
Brewer, M ;
Gershenson, DM ;
Herzog, CE ;
Mitchell, MF ;
Silva, EG ;
Wharton, JT .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2670-2675
[3]   Association of lymphadenectomy and survival in stage I ovarian cancer patients [J].
Chan, John K. ;
Munro, Elizabeth G. ;
Cheung, Michael K. ;
Husain, Amreen ;
Teng, Nelson N. ;
Berek, Jonathan S. ;
Osann, Kathryn .
OBSTETRICS AND GYNECOLOGY, 2007, 109 (01) :12-19
[4]  
Cooper GS, 2002, MED CARE, V40, P43
[5]   Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: A pediatric intergroup study - Pediatric Oncology Group 9049 and Children's Cancer Group 8882 [J].
Cushing, B ;
Giller, R ;
Cullen, JW ;
Marina, NM ;
Lauer, SJ ;
Olson, TA ;
Rogers, PC ;
Colombani, P ;
Rescorla, F ;
Billmire, DF ;
Vinocur, CD ;
Hawkins, EP ;
Davis, MM ;
Perlman, EJ ;
Castleberry, RP .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2691-2700
[6]   Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study [J].
Dimopoulos, MA ;
Papadimitriou, C ;
Hamilos, G ;
Efstathiou, E ;
Vlahos, G ;
Rodolakis, A ;
Aravantinos, G ;
Kalofonos, H ;
Kouroussis, C ;
Gika, D ;
Skarlos, D ;
Bamias, A .
GYNECOLOGIC ONCOLOGY, 2004, 95 (03) :695-700
[7]  
EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101
[8]   AFTER A TREATMENT BREAKTHROUGH - A COMPARISON OF TRIAL AND POPULATION-BASED DATA FOR ADVANCED TESTICULAR CANCER [J].
FEUER, EJ ;
FREY, CM ;
BRAWLEY, OW ;
NAYFIELD, SG ;
CUNNINGHAM, JB ;
GELLER, NL ;
BOSL, GJ ;
KRAMER, BS .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) :368-377
[9]  
Gershenson David M, 2005, J Natl Cancer Inst Monogr, P43